[144] Alnylam Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Alnylam Pharmaceuticals (ALNY) reported a proposed sale under Rule 144 of 31,448 common shares valued at $13,635,538.00 based on the filing. The shares were acquired and are to be sold on 08/14/2025 through UBS Financial Services, Inc. via the exercise of stock options and paid in cash. The filing lists 131,079,015 shares outstanding for the class. The filer reports no shares sold in the past three months. The notice includes the signer’s representation that they are unaware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Routine insider sale filing: exercise of options and immediate sale of 31,448 shares through UBS on 08/14/2025, no recent sales reported.

This Form 144 documents a standard Rule 144 notice for shares acquired by option exercise and intended for sale the same day. The transaction size (31,448 shares; aggregate value disclosed) is disclosed alongside the issuer's total outstanding shares, allowing basic dilution context. The filing does not report prior sales in the past three months, and it contains the customary representation about material nonpublic information. There are no additional details on price per share beyond the aggregate market value or any lock-up or trading-plan references.

Corporate Governance Expert

TL;DR: Administrative compliance filing; documents exercise-to-sale of common shares by a person affiliated with the company.

The Form 144 appears to fulfill disclosure obligations for an insider or affiliate disposing of shares under Rule 144. It specifies acquisition by option exercise and payment in cash, the broker used, and the planned sale date. The filing includes the required attestation about material information. No governance or compliance exceptions are indicated in the filing text provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010	31448	13635538.00	131079015	08/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/14/2025	Exercise of stock options	Issuer			31448	08/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the ALNY Form 144 propose to sell?

The filing proposes to sell 31,448 shares of Alnylam common stock.

When were the shares in the ALNY Form 144 acquired?

The shares were acquired on 08/14/2025 by exercise of stock options.

What is the aggregate market value reported in the ALNY Form 144?

The aggregate market value reported is $13,635,538.00.

Through which broker will the ALNY shares be sold?

The broker listed is UBS Financial Services, Inc. at 11 Madison Avenue, New York, NY.

Did the filer report any sales of ALNY shares in the past three months?

The filing states Nothing to Report for securities sold during the past three months.